Tech Patent Filing Process

Some of the “broadest” patent claims can actually be the riskiest. Broad independent claims serve an important purpose. They cover a wide scope, help prevent competitors from copying your product, and can discourage design arounds. But they come with tradeoffs that are easy to overlook, especially in crowded fields. A broad independent claim is more likely to overlap with the prior art. That often means more rejections and more amendments. If you are focused only on getting a broad claim, it can even result in a claim that never gets allowed in a meaningful form. That is why a layered claim strategy matters. A better approach is to pair a broad independent claim with a range of narrowing dependent claims. Some of those dependent claims should build on each other so that the end of the chain carves out a much narrower scope. Those narrower claims are often where allowance happens because they include features not found in the prior art. They are also where real enforcement value can come from when they align with the actual product. Another strategy I like is including a broad independent claim as claim 1 and a second, narrower independent claim later in the claim set. That narrower independent claim can move through prosecution more efficiently and gives you a fallback position without relying entirely on dependent claims. The goal is not just to get a patent. It is to get claims that survive examination and actually map onto the product in the market.

Inventors' Biggest Fear: “What if someone copies my idea with a small tweak and I lose everything?”🧐 You’re not alone. Many inventors hesitate to publish or launch their innovation fearing competitors might steal it with minor changes. Especially when your idea is a slight advancement, a new twist, a smarter design, a more efficient process and it feels vulnerable. So how do you protect your IP and sleep 🛌 better at night? Here’s a simple roadmap:👩🏻💼 ✅File a Provisional Patent Early- Secure your priority date. Even if your invention isn’t fully ready, this locks your idea legally before others can grab it. You get 12 months to finalize and file a complete patent. ✅ Use Trade Secrets Wisely- If your innovation includes a formula, recipe, or process that can be hidden, keep it confidential. Sign NDAs with employees and partners. Not everything needs to be patented to be protected. ✅Combine IP Rights- Use a mix of protections: ▪️Patent for technical novelty ▫️Design patent for product appearance ▪️Trademark for your brand name/logo ▫️Copyright for your manuals, designs, or code ✅ Broaden Your Patent Claims- Write your patent smartly. Cover not just the core feature but also possible variations competitors might attempt. A strong patent fence keeps copycats out. ✅ Publish Smartly (Defensive Publication) If you're not patenting something, publish it publicly. It becomes prior art, as a result, blocking others from getting a patent on a similar idea. 👩🏻💼You can consider this as a Real Example: A startup redesigned a coffee cup lid to prevent spills. Just a small tweak. They filed a provisional patent, kept the manufacturing technique a trade secret, and launched confidently. Today, their lid is in cafes across 3 countries, protected by strategy, not just fear. 👩🏻💼Don’t let fear kill your innovation. Protect it smartly. File early. Keep secrets. Use layered protection. Think like a creator and a strategist. #IPR #InnovationProtection #PatentStrategy

An expensive patenting mistake: One of the many reasons given for AstraZeneca pausing investment in the UK and considering moving its stock listing to the US was the cancellation of two SPCs linked to the patent for the antidiabetic agent dapagliflozin. As the NHS spends £300 million per year on this drug, the financial fallout to AZ will be immense. Why did this happen? Simply put, there wasn't any data on drug activity in the patent specification, therefore the patent is invalid for both lack of inventive step and insufficient disclosure. How this was missed in drafting and later in due diligence is a mystery, but it teaches us the following: (1) When drafting a patent application, especially for therapeutics, it's crucial to go beyond simply claiming a technical effect. You must provide data that makes the effect plausible. Since clinical data is often unavailable early on, include preclinical, in vitro, or in silico data to support your claims. Keep in mind you don't need to definitively prove your invention works, but the application must contain enough information for a skilled person to reasonably believe it would. This is known as plausibility. While you can use a priori reasoning or reference prior art to establish this, be careful not to make the invention seem obvious, as this could compromise its patentability. (2) For due diligence, carefully assess the data supporting a patent portfolio. The data must be robust and commensurate with the claims' scope. Patents that merely assert a technical effect without providing experimental results are vulnerable to attacks based on inventive step or sufficiency under current UK and European Patent Office standards. Therefore, having solid data is essential for a strong, defensible patent. https://lnkd.in/ea6tF9si

𝗧𝗵𝗲 "𝗘𝘅𝘁𝗲𝗿𝗻𝗮𝗹" 𝘃𝘀. "𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝗹" 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝘆 𝗳𝗼𝗿 𝗢𝘃𝗲𝗿𝗰𝗼𝗺𝗶𝗻𝗴 𝗣𝗮𝘁𝗲𝗻𝘁 𝗘𝗹𝗶𝗴𝗶𝗯𝗶𝗹𝗶𝘁𝘆 𝗥𝗲𝗷𝗲𝗰𝘁𝗶𝗼𝗻𝘀 When analyzing the USPTO's patent eligibility guidance under MPEP 2106, I've found it helpful to classify the various bases for determining subject matter eligibility into two broad categories: "external" and "internal." • 𝗘𝘅𝘁𝗲𝗿𝗻𝗮𝗹 factors focus on the purpose, function, or real-world application of the claimed invention. These include considerations like "improvements to the functioning of a computer," "practical application," and "applying or using the judicial exception in some other meaningful way beyond generally linking the use of the judicial exception to a particular technological environment." • 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝗹 factors focus on how the claimed invention achieves its purpose, such as the specific steps it performs or particular mechanisms it contains. These include considerations like use of a particular machine and transformation into a different state or thing. Understanding this distinction can be incredibly powerful when responding to patent eligibility rejections. Instead of confronting an examiner's rejection head-on, one strategy I've found to be useful is to shift the discussion, aikido-style, from one type of factor to another, by responding to an external rejection with internal arguments, or vice versa. For example: • If an examiner rejects your claim with the external argument that it's merely "directed to an abstract idea without practical application,” try pivoting to an 𝗶𝗻𝘁𝗲𝗿𝗻𝗮𝗹 factor, such as by arguing that your claim makes use of a particular machine or transforms subject matter into a different state or thing. • Conversely, if facing a rejection based on the 𝗶𝗻𝘁𝗲𝗿𝗻𝗮𝗹 argument that your claim "merely recites generic computer components performing generic functions," try redirecting attention to 𝗲𝘅𝘁𝗲𝗿𝗻𝗮𝗹 factors by showing how the claimed invention "improves the functioning of the computer itself" or integrates that alleged generic computer components into a patent-eligible practical application. This strategic approach allows you to avoid directly rebutting the basis for the Examiner's rejections, while still firmly grounding your arguments in the USPTO's guidance. It's like sidestepping a charging opponent and counter-attacking from a different angle, rather than meeting them head-on. Next time you face a Section 101 rejection, consider whether the examiner's reasoning is primarily based on 𝗲𝘅𝘁𝗲𝗿𝗻𝗮𝗹 or 𝗶𝗻𝘁𝗲𝗿𝗻𝗮𝗹 factors, then craft your response using factors from the other category. You might find that this approach shifts the focus of the discussion and can avoid the kind of repeated butting of heads that can drag out prosecution and delay allowance of valuable patents. #patents #patenteligibility #intellectualproperty

📝 Reviewing your first patent application? Before filing a patent application, patent attorneys generally ask their clients to review the draft application. Especially if this will be your first patent, this can be a bit daunting. Where to start? What to look for? Here are some tips: 1. Begin with the claims. They're the most important part as they will define what will be protected. 2. Check the detailed description. Its purpose is to support the claims. 3. Read the background section. It provides context for the invention but has only limited impact. Key steps when reviewing the claims: 1. ✅ Ensure all essential features are included 2. 🚩 Flag potential ambiguities or easy workarounds 3. 🔍 Verify what is claimed covers what you plan to do or sell 4. 🔢 Check for consistent use of terminology and proper claim references Key steps when reviewing the description: 1. 📚 Verify all claimed features are described 2. 💡 Highlight key advantages of your invention 3. 📏 Specify how measurement data is obtained 4. 🔗 Check all terminology is consistent with claims 5. 🖼️ Confirm figures are clear, labeled, and referenced 6. 🔬 Ensure sufficient detail for others in the field to reproduce the invention 7. ⚙️ Include all feasible variations and embodiments unless there are strategic reasons to do otherwise Remember, as an inventor, you know the invention best. Your input is thus crucial in ensuring the application accurately and comprehensively describes the invention. Also take the time you need to thoroughly review the draft. A patent application is a significant investment and once filed, no new information can be added. Good luck reviewing! And if you have any further helpful tips or experiences, please share them in the comments below.

#enforcement #patents #productstrategy #ip Many patents look strong at first glance but lose impact when enforced, often because the claim strategy doesn’t match how the technology is used. Think of a car: a method claim might cover how a driver presses the accelerator and how the system adjusts torque; great in theory, but risky if different parties perform different steps. A system claim instead focuses on the throttle sensor, processor, and motor controller; much cleaner when targeting manufacturers. And modern products benefit from a Beauregard (computer readable medium) claim, capturing the software that calculates torque and generates control signals. By combining method, system, and CRM claims, you protect how the car is used, what it physically is, and what its software actually does; creating a far more enforceable and future‑proof patent strategy.

Your patent examiner isn't your enemy. But they’re not your friend either. There’s a line between advocacy and collegiality. Most attorneys miss it. I’ve seen both extremes. On one hand, the “screamer” arguing the examiner is wrong until they’re red in the face, filing a 30-page response explaining everything the examiner “got wrong,” while moving the case nowhere. As a former patent examiner myself, that was the attorney I least wanted to work with. But the opposite is just as bad. The attorney who amends everything, whether it’s warranted or not. That helps the examiner, but not the client. Good patent advocacy is not about winning arguments. And it’s not about conceding ground. It’s about controlled movement. Moving the record forward without giving up meaningful scope. Three things that work: First, strategic clarifying amendments. Not narrowing, just clarifying. Enough to distinguish over the prior art and maintain compact prosecution. Second, targeted examiner interviews. Not every case needs one. But when there’s a real impasse, an interview can unlock allowance. Third, non-personal advocacy. Don’t attack the examiner. Reframe the issue. “The present claims are not obvious” lands better than “the examiner failed to make a prima facie case.” Same point. Different outcome. Examination is not adversarial. It’s a dialogue. And the attorneys who understand that get stronger patents. Strong prosecution isn’t aggressive or passive. It’s precise. It’s strategic. It’s effective. #patentlaw #intellectualproperty #patents #ipstrategy #innovation

Patent Pro Tip: consider seeking synergy between 101 and 102/103 arguments to streamline prosecution for software patent applications 🔀 Patent applicants usually seek to streamline prosecution (back-and-forth with the patent office) as much as possible. ⏩ For applications facing both 101 eligibility rejections and 102/103 art-based rejections, finding amendments and arguments that synergize toward advancing prosecution on both fronts can translate to more efficient prosecution. 👍 What might this synergy look like? 🤔 Generally speaking, the idea would be to pick claim features (either existing or added via amendment) which both: 1) Help with eligibility, for example by demonstrating a computer or other technology improvement; and 2) Distinguish from the prior art How do you identify these features? ❓❓❓ The key often lies in having a firm grasp of the core innovation as well as the technical details which contribute to 101 eligibility. 🔑 Find claim features which exist in the area of overlap between core innovations that the references fail to teach, and ways to improve computer/technology performance. 🔀 Think along the lines (curves?) of a Venn diagram and try to find claim features which fall into both the “overcomes 101 rejection” circle as well as the “overcomes 102/103 rejections circle.” 🔘 In some cases, this may help yield better patents more efficiently. 👌 What are your #PatentProTips for increasing prosecution efficiency?

The $2.23 billion bet on small molecule drugs is failing, not in the lab, but in the patent office. The structural weakness is clear: a mere five years of NCE exclusivity compared to 12 for biologics. Innovators relying solely on a core Composition of Matter (CoM) patent are accelerating their own generic cliff. This traditional, molecule-centric approach is now commercially obsolete. The pressure to recoup soaring R&D costs demands immediate action. Maximum ROI demands a radical shift to a "lifecycle-centric" IP strategy—a sophisticated Patent Fortress. Securing foundational CoM claims remains critical, ideally using a provisional filing to establish the earliest possible priority date and gain a 12-month development window. But maximizing market longevity requires continuous IP generation, integrating patent filing into every stage of R&D. The goal is to aggressively compensate for the statutory exclusivity deficit and ensure the effective market term approaches the 14-year maximum set by Patent Term Extension (PTE) rules. The robust defense perimeter consists of meticulously crafted secondary patents designed to survive Paragraph IV challenges and create regulatory barriers. Polymorph patents are the high-stakes layer; they claim specific crystalline forms, blocking generic formulation workarounds and triggering costly, 30-month litigation stays via Orange Book listing. This technical rigor translates directly into retained revenue. Beyond polymorphs, advanced Formulation Patents protect specific drug delivery systems and excipient ratios, provided they demonstrate an "unexpected benefit" that enhances bioavailability or stability. Furthermore, strategic Method of Use claims for new dosing regimens or patient subsets can secure an additional three years of New Clinical Investigation Exclusivity. Every secondary claim, every year of delay against generic entry, is a massive win. This isn't just legal strategy; it's sophisticated regulatory engineering essential for commercial success and shareholder value. #Drugs #Patents #Generics https://lnkd.in/eWSCAfBh